Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties

Frontiers in Physiology

Volumn 6, Issue JUL, 2015, Pages

  Lepojärvi, E Samuli ^a   Piira, Olli Pekka ^a   Pääkkö, Eija ^b   Lammentausta, Eveliina ^b   Risteli, Juha ^c   Miettinen, Johanna A ^a   Perkiömäki, Juha S ^a   Huikuri, Heikki V ^a   Junttila, M Juhani ^a  

^a MEDICAL RESEARCH CENTER OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Biomarkers; Diastolic heart failure; Doppler echocardiography; Fibrosis; Magnetic resonance imaging

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; COLLAGEN; GADOTERATE MEGLUMINE; GALECTIN 3; HEMOGLOBIN A1C; INTERLEUKIN RECEPTOR; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTEIN PRECURSOR; ST2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CHOLESTEROL BLOOD LEVEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMAGE ANALYSIS; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RELAXATION TIME; SENSITIVITY AND SPECIFICITY; TISSUE DOPPLER IMAGING;

EID: 84940048340     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2015.00200     Document Type: Article

References (21)

1. Bayes-Genis, A., De Antonio, M., Galán, A., Sanz, H., Urrutia, A., Cabanes, R., et al. (2012). Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur. J. Heart Fail. 14, 32-38. doi: 10.1093/eurjhf/hfr156.
2. Christenson, R. H., Duh, S., Wu, A. H. B., Smith, A., Abel, G., deFilippi, C. R., et al. (2010). Multi-center determination of galectin-3 assay performance characteristics:. Anatomy of a novel assay for use in heart failure. Clin. Biochem. 43, 683-690. doi: 10.1016/j.clinbiochem.2010.02.001.
3. Cicoira, M., Rossi, A., Bonapace, S., Zanolla, L., Golia, G., Franceschini, L., et al. (2004). Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J. Card. Fail. 10, 403-411. doi: 10.1016/j.cardfail.2004.01.010.
4. De Boer, R. A., Lok, D. J. A., Jaarsma, T., van der Meer, P., Voors, A. A., Hillege, H. L., et al. (2011). Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 43, 60-68. doi: 10.3109/07853890.2010.538080.
5. Eggers, K. M., Armstrong, P. W., Califf, R. M., Simoons, M. L., Venge, P., Wallentin, L., et al. (2010). ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am. Heart J. 159, 788-794. doi: 10.1016/j.ahj.2010.02.022.
6. Ellims, A. H., Shaw, J. A., Stub, D., Iles, L. M., Hare, J. L., Slavin, G. S., et al. (2014). Diffuse myocardial fibrosis evaluated by post-contrast T1 mapping correlates with left ventricular stiffness. J. Am. Coll. Cardiol. 63, 1112-1118. doi: 10.1016/j.jacc.2013.10.084.
7. Ho, J. E., Liu, C., Lyass, A., Courchesne, P., Pencina, M. J., Vasan, R. S., et al. (2012). Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 60, 1249-1256. doi: 10.1016/j.jacc.2012.04.053.
8. Iles, L., Pfluger, H., Phrommintikul, A., Cherayath, J., Aksit, P., Gupta, S. N., et al. (2008). Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J. Am. Coll. Cardiol. 52, 1574-1580. doi: 10.1016/j.jacc.2008.06.049.
9. Jellis, C., Wright, J., Kennedy, D., Sacre, J., Jenkins, C., Haluska, B., et al. (2011). Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy. Circ. Cardiovasc. Imaging 4, 693-6702. doi: 10.1161/circimaging.111.963587.
10. Koivula, M., Richardson, J., Leino, A., Valleala, H., Griffiths, K., Barnes, A., et al. (2010). Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay. Clin. Biochem. 43, 1453-1457. doi: 10.1016/j.clinbiochem.2010.09.019.
11. Lok, D. J. A., Van Der Meer, P., Bruggink-André De La Porte, P. W., Lipsic, E., Van Wijngaarden, J., Hillege, H. L., et al. (2010). Prognostic value of galectin-3, a novel marker of fibrosis,in patients with chronic heart failure: Data from the DEAL-HF study. Clin. Res. Cardiol. 99, 323-328. doi: 10.1007/s00392-010-0125-y.
12. Lok, D. J., Lok, S. I., Bruggink-André De La Porte, P. W., Badings, E., Lipsic, E., van Wijngaarden, J., et al. (2013). Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin. Res. Cardiol. 102, 103-110. doi: 10.1007/s00392-012-0500-y.
13. Lopez-Andrés, N., Rossignol, P., Iraqi, W., Fay, R., Nuée, J., Ghio, S., et al. (2012). Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF (cardiac resynchronization in heart failure) trial. Eur. J. Heart Fail. 14, 74-81. doi: 10.1093/eurjhf/hfr151.
14. Manzano-Fernandez, S., Mueller, T., Pascual-Figal, D., Truong, Q. A., and Januzzi, J. L. (2011). Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am. J. Cardiol. 107, 259-267. doi: 10.1016/j.amjcard.2010.09.011.
15. Miller, C. A., Naish, J. H., Bishop, P., Coutts, G., Clark, D., Zhao, S., et al. (2013). Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ. Cardiovasc. Imaging 6, 373-383. doi: 10.1161/circimaging.112.000192.
16. Ng, A. C. T., Auger, D., Delgado, V., van Elderen, S. G., Bertini, M., Siebelink, H. M., et al. (2012). Association between diffuse myocardial fibrosis by cardiac magnetic resonance contrast-enhanced T1 mapping and subclinical myocardial dysfunction in diabetic patients a pilot study. Circ. Cardiovasc. Imaging 5, 51-59. doi: 10.1161/circimaging.111.965608.
17. Pascual-Figal, D. A., Ordoñez-Llanos, J., Tornel, P. L., Vázquez, R., Puig, T., Valdés, M., et al. (2009). Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 54, 2174-2179. doi: 10.1016/j.jacc.2009.07.041.
18. Raman, S. V., Moreo, A., Ambrosio, G., De Chiara, B., Pu, M., Tran, T., et al. (2009). Influence of myocardial fibrosis on left ventricular diastolic function noninvasive assessment by cardiac magnetic resonance and echo. Circ. Cardiovasc. Imaging 2, 437-443. doi: 10.1161/CIRCIMAGING.108.838367.
19. Risteli, J., Niemi, S., Trivedi, P., Maentausta, O., Mowat, A. P., and Risteli, L. (1988). Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin. Chem. 34, 715-718.
20. Rusinaru, D., Houpe, D., Szymanski, C., Levy, F., Marechaux, S., and Tribouilloy, C. (2014). Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur. J. Heart Fail. 16, 967-976. doi: 10.1002/ejhf.142.
21. Velagaleti, R. S., Gona, P., Sundström, J., Larson, M. G., Siwik, D., Colucci, W. S., et al. (2010). Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality. Arterioscler. Thromb. Vasc. Biol. 30, 2283-2288. doi: 10.1161/ATVBAHA.110.208462.